The global LDL test market size was valued at USD 9.3 billion in 2025 and is projected to grow from USD 9.87 billion in 2026 to USD 15.91 billion by 2034, registering a CAGR of 6.15% during the forecast period from 2026 to 2034. Asia Pacific dominated the LDL test market with a market share of 38.6% in 2025.
An LDL test is a diagnostic blood test used to measure the level of low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol. High LDL levels can lead to plaque buildup in the arteries, increasing the risk of heart disease and stroke. The test is commonly included in lipid profile screenings to evaluate cardiovascular health and guide treatment decisions.
Download a Free Sample To learn more about this report,
Expansion of Point-of-Care Lipid Testing
The LDL test market is moving toward decentralized testing as healthcare providers look for faster ways to assess lipid levels outside central laboratories. Point-of-care analyzers can provide lipid measurements closer to patients and support screening, treatment monitoring, and cardiovascular risk assessment. This is increasing the importance of compact analyzers, dedicated test cartridges, and near-patient workflows within modern diagnostic services.
Greater Use of LDL Measurements in More Comprehensive Cardiovascular Risk Assessment
LDL testing is increasingly being considered alongside other lipid and cardiovascular-risk markers rather than as an isolated measurement. This is encouraging diagnostic providers and laboratories to support broader lipid assessment, including additional biomarkers that can help identify patients with inherited or elevated cardiovascular risk. As clinical assessment becomes more comprehensive, testing platforms are adapting to provide physicians with a wider range of information for preventive and treatment decisions.
In September 2025, the CDC reported that familial hypercholesterolemia affects approximately 1 in 311 people and emphasized the importance of identifying and treating the condition early, reinforcing the clinical relevance of LDL measurement in patients with inherited cholesterol risk.
Routine Cholesterol Screening Creates Recurring Testing Demand
Regular testing also supports identification of elevated cholesterol before symptoms appear. This recurring need across primary care, hospitals, diagnostic laboratories, and outpatient settings provides a broad foundation for LDL test market growth.
The American Heart Association states that cholesterol screening every five years generally works well for most adults beginning at age 19, while the appropriate testing frequency can vary according to individual risk factors.
Measurement Complexity Can Limit Result Consistency
LDL measurement is subject to methodological differences between direct assays, calculated values, and newer estimation approaches. Differences in triglyceride concentrations and other analytical factors can affect how LDL-C is determined, creating challenges when results from different methods need to be compared. Laboratories therefore require validated analytical procedures and appropriate quality controls, which can increase operational requirements.
Recent research published in 2026 reviewed newly developed equations for calculating LDL cholesterol and related lipid measures, highlighting continuing scientific efforts to improve LDL estimation methods.
Growing Demand for Expanded Lipid Testing Panels
Testing for markers such as lipoprotein(a) can provide additional information for identifying inherited or otherwise elevated cardiovascular risk. This creates opportunities for diagnostic companies to develop broader lipid-testing panels and laboratory workflows that provide clinicians with more comprehensive information.
In March 2026, the American Heart Association highlighted updated cholesterol guidance recommending that every adult receive a lipoprotein(a) test at least once during their lifetime, increasing the potential role of expanded lipid testing alongside conventional LDL assessment.
Keeping LDL Testing Aligned With Changing Clinical Targets
Diagnostic providers face the challenge of ensuring that LDL testing remains aligned with changing clinical recommendations and treatment thresholds. As clinical guidelines increasingly use LDL-C targets for different levels of cardiovascular risk, laboratories need dependable measurements that clinicians can interpret against the appropriate thresholds. This places continued emphasis on analytical quality, standardized reporting, and compatibility between diagnostic results and clinical decision-making.
In March 2026, the ACC and AHA released an updated dyslipidemia guideline that reinstated LDL-C treatment goals, including targets of below 100 mg/dL for borderline or intermediate-risk patients and below 70 mg/dL for high-risk patients.
LDL-C Dominated the Market with 62.4% Share in 2025
The LDL-C segment accounted for the largest share of the global LDL test market at 62.4% in 2025, driven by the increasing prevalence of cardiovascular diseases, rising awareness of cholesterol management, and widespread adoption of LDL cholesterol testing for routine health screenings and preventive healthcare.
Request Customizationto receive a tailored report.
Kits and Reagents are Projected to Register the Fastest Growth at a CAGR of 7.81%
The kits and reagents segment is expected to register the fastest growth at a CAGR of 7.81% during 2026–2034, supported by growing demand for accurate diagnostic testing, increasing laboratory testing volumes, and continuous advancements in assay technologies that enhance testing efficiency and reliability.
Dyslipidemia Dominated the Market with 24.9% Share in 2025
The dyslipidemia segment held the largest share of the global LDL test market at 24.9% in 2025, owing to the rising incidence of abnormal lipid levels, increasing lifestyle-related disorders, and greater emphasis on early diagnosis and continuous monitoring to reduce the risk of cardiovascular complications.
Diagnostic Centers are Projected to Register the Fastest Growth at a CAGR of 7.92%
The diagnostic centers segment is projected to register the fastest growth at a CAGR of 7.92% during 2026–2034, driven by expanding access to specialized diagnostic services, increasing patient preference for outpatient testing, and growing investments in advanced laboratory infrastructure to deliver rapid and accurate lipid profile testing.
Speak to an Analystto discuss market opportunities.
Asia Pacific accounted for 38.6% of the LDL test market, valued at USD 3.59 billion in 2025, making it the largest regional market. The region is experiencing strong growth due to increasing cardiovascular disease prevalence, expanding preventive healthcare programs, rising healthcare expenditure, and improving diagnostic laboratory infrastructure. Growing awareness of cholesterol screening and government health initiatives continue to support market expansion.
China accounted for an estimated USD 2.08 billion in 2025, representing the largest share of the Asia Pacific market. Rising incidences of cardiovascular disorders, expanding diagnostic laboratory networks, increasing healthcare investments, and growing adoption of advanced lipid testing technologies continue to drive market growth.
Japan generated an estimated USD 0.65 billion in 2025. The country's aging population, strong preventive healthcare system, widespread routine health checkups, and advanced diagnostic capabilities continue to support steady market development.
Unlock Regional Insightsto access country-level data, & regional trends.
North America accounted for 29.4% of the market, reaching USD 2.73 billion in 2025. The regional market is driven by a high prevalence of lifestyle-related cardiovascular diseases, advanced diagnostic infrastructure, and widespread adoption of routine lipid profile testing. Favorable reimbursement policies and increasing preventive healthcare awareness further contribute to market growth.
The United States accounted for an estimated USD 2.38 billion in 2025, representing the largest share of the North American market. Growth is supported by increasing cardiovascular screening programs, strong healthcare spending, and the availability of advanced laboratory testing technologies.
Canada generated an estimated USD 0.35 billion in 2025. Rising awareness of cardiovascular risk factors, expanding preventive healthcare initiatives, and increasing utilization of diagnostic testing services continue to support market expansion.
Europe accounted for 21.7% of the market, valued at USD 2.02 billion in 2025. The regional market benefits from established healthcare systems, increasing demand for early disease diagnosis, and government-supported preventive health screening programs. Rising adoption of automated diagnostic platforms further supports steady market growth.
Germany accounted for an estimated USD 0.55 billion in 2025. The country's advanced healthcare infrastructure, high diagnostic testing volumes, and increasing focus on cardiovascular disease prevention continue to drive market expansion.
The United Kingdom generated an estimated USD 0.44 billion in 2025. Growing public health screening initiatives, increasing adoption of advanced diagnostic technologies, and rising awareness of cholesterol management continue to support market growth.
The Middle East and Africa represented 4.5% of the market, totaling USD 0.42 billion in 2025. Rising healthcare investments, increasing awareness of cardiovascular diseases, and expanding diagnostic laboratory infrastructure are contributing to market growth. Government initiatives aimed at improving chronic disease management are creating additional opportunities.
The United Arab Emirates accounted for an estimated USD 0.10 billion in 2025. Growing preventive healthcare programs, expanding private healthcare facilities, and increasing adoption of advanced laboratory diagnostics continue to support market expansion.
Africa generated an estimated USD 0.32 billion in 2025. Improving access to diagnostic services, rising prevalence of non-communicable diseases, and expanding healthcare infrastructure continue to drive steady market development across the region.
Latin America accounted for 5.8% of the market, valued at USD 0.54 billion in 2025. The regional market is supported by increasing healthcare expenditure, growing awareness of cardiovascular disease prevention, and expanding access to diagnostic testing. Rising investments in healthcare infrastructure continue to foster market growth.
Brazil accounted for an estimated USD 0.23 billion in 2025, making it the largest market in Latin America. Increasing routine health screenings, growing diagnostic laboratory capacity, and rising awareness of cholesterol management continue to drive market growth.
Mexico generated an estimated USD 0.15 billion in 2025. Expanding preventive healthcare programs, increasing demand for lipid profile testing, and improving healthcare accessibility continue to support steady market expansion.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Fetal Bovine Serum Market Size, Share, Growth, Analysis, 2034
Automated Microbiology Market Size, Share, Growth, Analysis, 2034
Assisted Reproductive Technology Market Size, Share, Growth, 2034
U.S Direct to Consumer Laboratory Testing Market Size, Share and Forecast to 2034
Ontogenetic Market Size, Share, Growth, Analysis, Report, 2034
Transfer Membrane Market Size, Share, Growth, Forecast, 2034
We are featured on:
sales@straitsresearch.com